Download PDF
Aktuelle Neurologie 2006; 33(7): 394-402
DOI: 10.1055/s-2005-915466
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Behandlung von nicht-motorischen Symptomen im fortgeschrittenen Stadium des M. Parkinson

Management of Nonmotor Symptoms in Advanced Parkinson DiseaseG.  Ellrichmann1 , W.  Kuhn2 , T.  Müller1
  • 1Department of Neurology, St. Josef-Hospital, Ruhr University Bochum
  • 2Department of Neurology, Schweinfurt, Germany
Further Information

Publication History

Publication Date:
19 April 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Gegenwärtige medikamentöse Therapien sind in frühen Krankheitsstadien des Morbus Parkinson wirksam. Die Behandlung im fortgeschrittenen Stadium des Morbus Parkinson bleibt jedoch für Arzt und Patient eine Herausforderung. Trotz großem Nutzen der dopaminergen Therapie ist die Langzeitbehandlung bei der Mehrzahl der Patienten sowohl mit motorischen als auch mit nicht-motorischen Komplikationen verbunden. Letztere stellen eine wichtige Ursache der Behinderung vieler Parkinson-Patienten dar. Deshalb sollten Fortschritte in Prävention und Therapie solcher nicht-motorischer Probleme erreicht werden, was der Hauptaspekt dieser Übersicht ist.

Abstract

Current medical therapies for Parkinson disease (PD) are very effective in managing the early stages of the disorder. However, management of patients with advanced stage of PD remains a challenge for the physician and the patient. Despite many benefits of dopaminergic therapy, long-term treatment is associated with both motor and non-motor complications in the majority of patients. Last named are main sources of disability for many PD patients. Therefore, advances in the ability to prevent and treat these problems are critical in the management of these patients and are the major focus of this survey.

Literatur

  • 1 Murai T, Muller U, Werheid K. et al . In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease.  J Neuropsychiatry Clin Neurosci. 2001;  13 222-228
    PubMedGoogle Scholar
  • 2 Sano M, Stern Y, Williams J. et al . Coexisting dementia and depression in Parkinson's disease.  Arch Neurol. 1989;  46 1284-1286
    PubMedGoogle Scholar
  • 3 Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism.  Neurology. 1986;  36 1130-1133
    CrossrefPubMedGoogle Scholar
  • 4 Cummings J L. Depression and Parkinson's disease: a review.  Am J Psychiatry. 1992;  149 443-454
    PubMedGoogle Scholar
  • 5 Gotham A M, Brown R G, Marsden C D. Depression in Parkinson's disease: a quantitative and qualitative analysis.  J Neurol Neruosurg Psychiatry. 1986;  49 381-389
    CrossrefPubMedGoogle Scholar
  • 6 Huber S J, Paulson G W, Shuttleworth E C. Relationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease.  Neurosurg Psychiatry. 1988;  51 855-858
    PubMedGoogle Scholar
  • 7 Tandberg E, Larsden J P, Aarsland D. et al . The occurrence of depression in Parkinson's disease. A community-based study.  Arch Neurol. 1996;  53 175-179
    PubMedGoogle Scholar
  • 8 Walsh K, Bennett G. Parkinson's disease and anxiety.  Postgrad Med J. 2001;  77 89-93
    CrossrefPubMedGoogle Scholar
  • 9 Shulman L M, Taback R L, Bean J. et al . Comorbidity of the nonmotor symptoms of Parkinson's disease.  Mov Disord. 2001;  16 507-510
    CrossrefPubMedGoogle Scholar
  • 10 Mayeux R, Stern Y, Cote L. et al . Altered serotonin metabolism in depressed patients with Parkinson's disease.  Neurology. 1984;  34 642-646
    PubMedGoogle Scholar
  • 11 Mayeux R, Stern Y, Sano M. et al . The relationsship of serotonin to depression in Parkinson's disease.  Mov Disord. 1988;  3 237-244
    CrossrefPubMedGoogle Scholar
  • 12 Raisman R, Cash R, Agid Y. Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine bindings sites in putamen.  Neurology. 1986;  36 556-560
    PubMedGoogle Scholar
  • 13 Ring H A, Bench C J, Trimble M R. et al . Depression in Parkinson's disease. A positron emission study.  Br J Psychiatry. 1994;  165 333-339
    CrossrefPubMedGoogle Scholar
  • 14 Mayberg H S, Starkstein S E, Sadzot B. et al . Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease.  Ann Neurol. 1990;  28 57-64
    CrossrefPubMedGoogle Scholar
  • 15 Sargent P A, Kjaer K H, Bench C J. et al . Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-1 000 635: effects of depression and antidepressant treatment.  Arch Gen Psychiatry. 2000;  57 174-180
    CrossrefPubMedGoogle Scholar
  • 16 Lemke M R, Fuchs G, Gemende I. et al . Depression and Parkinson's disease.  J Neurol. 2004;  251, Suppl 6 VI/24-27
    PubMedGoogle Scholar
  • 17 Lemke M R. Motor signs of depression.  Nervenarzt. 1999;  70 600-612
    CrossrefPubMedGoogle Scholar
  • 18 Fukunishi I, Hosokawa K, Ozaki S. Depression antedating the onset of Parkinson's disease.  JPN J Psychiatry Neurol. 1991;  45 7-11
    PubMedGoogle Scholar
  • 19 Steuer E N, Ballering L A. Moclobemide and selegeline in the treatment of depression in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1997;  3 547
    PubMedGoogle Scholar
  • 20 Lees A J, Shaw K M, Kohout L J. et al . Deprenyl in Parkinson's disease.  Lancet. 1977;  2 791-795
    PubMedGoogle Scholar
  • 21 Moller J C, Oertel W H, Koster J. et al . Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.  Mov Disord. 2005;  20 602-610
    CrossrefPubMedGoogle Scholar
  • 22 Rektorova I, Rektor I, Bares M. et al . Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.  Eur J Neurol. 2003;  10 399-406
    CrossrefPubMedGoogle Scholar
  • 23 Reichmann H, Brecht M H, Koster J. et al . Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease.  CNS Drugs. 2003;  17 965-973
    CrossrefPubMedGoogle Scholar
  • 24 Parkinson Study Group . Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.  J Am Med Assoc. 2002;  287 1653-1661
    CrossrefPubMedGoogle Scholar
  • 25 Whone A L, Watts R L, Stoessl A J. et al . Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study.  Ann Neurol. 2003;  54 93-101
    CrossrefPubMedGoogle Scholar
  • 26 Tesei S, Antonini A, Canesi M. et al . Tolerability of paroxetine in Parkinson's disease: a prospective study.  Mov Disord. 2000;  15 986-989
    CrossrefPubMedGoogle Scholar
  • 27 Richard I H, Kurlan R. A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group.  Neurology. 1997;  49 1168-1170
    PubMedGoogle Scholar
  • 28 Hauser R A, Zesiewicz T A. Sertraline for the treatment of depression in Parkinson's disease.  Mov Disord. 1997;  12 756-759
    CrossrefPubMedGoogle Scholar
  • 29 Ceravolo R, Nuti A, Piccinni A. et al . Paroxetine in Parkinson's disease: effects on motor and depressive symptoms.  Neurology. 2000;  55 1216-1218
    PubMedGoogle Scholar
  • 30 Richard I H, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series.  Mov Disord. 1999;  14 155-157
    CrossrefPubMedGoogle Scholar
  • 31 Montgomery S A. Reboxetine: additional beliefs to the depressed patients.  J Psychopharmacol. 1997;  11, suppl S9-15
    PubMedGoogle Scholar
  • 32 Fbrowm W A. Are antidepressants as ineffective as they look?.  Prevention & Treatment. 2002;  5 , article 25
    PubMedGoogle Scholar
  • 33 International Marketing Services Health (2004) .Year-end U. S. Prescription and sales information and commentary. Fairfield (Connecticut); 2005
    Google Scholar
  • 34 Moellentine C, Rummans T, Ahlskog J E. et al . Effectiveness of ECT in patients with parkinsonism.  J Neuropsychiatry Clin Neurosci. 1998;  10 187-193
    PubMedGoogle Scholar
  • 35 Fuchs G A, Gemende I, Herting B. et al . Dementia in idiopathic Parkinson's syndrome.  J Neurol. 2004;  251, Suppl 6 VI/28-32
    PubMedGoogle Scholar
  • 36 Cummings J L. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates.  J Geriatr Psychiatry Neurol. 1988;  1 24-36
    CrossrefPubMedGoogle Scholar
  • 37 Aarsland D, Tandberg E, Larsden J P. et al . Frequency of dementia in Parkinson's disease.  Arch Neurol. 1996;  53 538-542
    PubMedGoogle Scholar
  • 38 Levy G, Schupf N, Tang M X. et al . Combined effect of age and severity on the risk of dementia in Parkinson's disease.  Ann Neurol. 2002;  51 722-729
    CrossrefPubMedGoogle Scholar
  • 39 Emre M. What causes mental dysfunction in Parkinson's disease?.  Mov Disord. 2003;  18, Suppl 6 S63-71
    CrossrefPubMedGoogle Scholar
  • 40 Emre M. Dementia associated with Parkinson's disease.  Lancet Neurol. 2003;  2 229-237
    CrossrefPubMedGoogle Scholar
  • 41 Perry E K, Irving D, Kerwin J M. et al . Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease.  Alzheimer Dis Assoc Disord. 1993;  7 69-79
    PubMedGoogle Scholar
  • 42 Braak H, Rub U, Jansen Steur E N. et al . Cognitive status correlates with neuropathologic stage in Parkinson's disease.  Neurology. 2005;  64 1404-1410
    CrossrefPubMedGoogle Scholar
  • 43 Braak H, Tredici K Del, Rub U. et al . Staging of brain pathology related to sporadic Parkinson's disease.  Neurobiol Aging. 2003;  24 197-211
    CrossrefPubMedGoogle Scholar
  • 44 Lees A J, Smith E. Cognitive deficits in the early stages of Parkinson's disease.  Brain. 1983;  106 257-270
    PubMedGoogle Scholar
  • 45 Levy G, Tang M X, Louis E D. et al . The association of incident dementia with mortality in PD.  Neurology. 2002;  59 1708-1713
    PubMedGoogle Scholar
  • 46 Louis E D, Marder K, Cote L. et al . Mortality from Parkinson disease.  Arch Neurol. 1997;  54 260-264
    PubMedGoogle Scholar
  • 47 Sacks O W, Kohl M S, Messeloff C R. et al . Effects of levodopa in Parkinsonian patients with dementia.  Neurology. 1972;  22 516-519
    PubMedGoogle Scholar
  • 48 Hietanen M, Teravainen H. Dementia and treatment with L-dopa in Parkinson's disease.  Mov Disord. 1988;  3 263-270
    CrossrefPubMedGoogle Scholar
  • 49 Emre M, Aarsland D, Albanese A. et al . Rivastigmin for dementia associated with Parkinson's Disease.  N Engl J Med. 2004;  351 2509-2518
    CrossrefPubMedGoogle Scholar
  • 50 Leroi I, Brandt J, Reich S G. et al . Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.  Int J Geriatr Psychiatry. 2004;  19 1-8
    CrossrefPubMedGoogle Scholar
  • 51 Aarsland D, Hutchinson M. Galantamine for Parkinson's disease with dementia.  Eur Neuropsychopharm. 2002;  12, Suppl 12 S378-379
    PubMedGoogle Scholar
  • 52 Goetz C G. Hallucinations in Parkinson's disease: the clinical syndrome.  Adv Neurol. 1999;  80 419-423
    PubMedGoogle Scholar
  • 53 Fenelon G, Mahieux F, Huon R. et al . Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.  Brain. 2000;  123 733-745
    CrossrefPubMedGoogle Scholar
  • 54 Sanchez-Ramos J R, Ortoll R, Paulson G W. Visual hallucinations associated with Parkinson disease.  Arch Neurol. 1996;  53 1265-1268
    PubMedGoogle Scholar
  • 55 Kulisevsky J, Roldyn E. Hallucinations and sleep disturbances in Parkinson's disease.  Neurology. 2004;  63 (8, Suppl 3) S28-30
    PubMedGoogle Scholar
  • 56 Rondot P, Recondo J De, Coignet A. et al . Mental disorders in Parkinson's disease after treatment with L-Dopa.  Adv Neurol. 1984;  40 259-269
    PubMedGoogle Scholar
  • 57 Zoldan J, Friedberg G, Livneh M. et al . Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist.  Neurology. 1995;  45 1305-1308
    PubMedGoogle Scholar
  • 58 The Parkinson Study Group . Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease.  N Engl J Med. 1999;  340 757-763
    CrossrefPubMedGoogle Scholar
  • 59 Meco G, Alessandri A, Giustini P. et al . Risperdone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study.  Mov Disord. 1997;  12 610-612
    CrossrefPubMedGoogle Scholar
  • 60 Lang A E, Sandor P, Duff J. Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis.  Clin Neuropharmacol. 1995;  18 39-45
    PubMedGoogle Scholar
  • 61 Spieker S, Stetter F, Klockgether T. Zotepine in levodopa-induced psychosis.  Mov Disord. 1995;  10 795-797
    CrossrefPubMedGoogle Scholar
  • 62 Wolters E C, Jansen E N, Tuynman-Qua H G. et al . Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.  Neurolog. 1996;  47 1085-1087
    CrossrefPubMedGoogle Scholar
  • 63 Force M DT. Drugs to treat dementia and psychosis.  Mov Disord. 2002;  17 120-127
    CrossrefPubMedGoogle Scholar
  • 64 Targum S D, Abbott J L. Efficacy of quetiapine in Parkinson's patients with sychosis.  J Clin Psychopharmacol. 2000;  20 54-60
    CrossrefPubMedGoogle Scholar
  • 65 Fernandez H H, Friedman J H, Jacques C. et al . Quetiapine for the treatment of drug induces psychosis in Parkinson's disease.  Mov Disord. 1999;  14 484-487
    CrossrefPubMedGoogle Scholar
  • 66 Goetz C G, Blasucci L M, Leurgans S. et al . Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.  Neurology. 2000;  55 789-794
    CrossrefPubMedGoogle Scholar
  • 67 Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease.  Clin Neuropharmacol. 2002;  25 107-110
    PubMedGoogle Scholar
  • 68 Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.  Curr Med Res Opin. 2002;  18 258-264
    CrossrefPubMedGoogle Scholar
  • 69 Martignoni E, Pacchetti C, Godi L. et al . Automatic disorders in Parkinson's disease.  J Neural Transm Suppl. 1995;  45 11-19
    PubMedGoogle Scholar
  • 70 Swinn L, Schrag A, Viswanathan R. et al . Sweating dysfunction in Parkinson's disease.  Mov Disord. 2003;  18 1459-1463
    CrossrefPubMedGoogle Scholar
  • 71 Yu M, Roane D M, Miner C R. et al . Dimensions of sexual dysfunction in Parkinson's disease.  Am J Geriatr Psychiatry. 2004;  12 221-226
    PubMedGoogle Scholar
  • 72 Hunter S. The rostral mesencephalon in Parkinson's disease and Alzheimer's disease.  Acta Neuropathol (Berl). 1985;  68 53-58
    CrossrefPubMedGoogle Scholar
  • 73 Langston J W, Forno L S. The hypothalamus in Parkinson's disease.  Ann Neurol. 1978;  3 129-133
    CrossrefPubMedGoogle Scholar
  • 74 Ohama E, Ikuta F. Parkinson's disease: distribution of Lewy bodies and monoamine neuron system.  Acta Neuropathol (Berl). 1976;  34 311-319
    CrossrefPubMedGoogle Scholar
  • 75 Goldstein D S. Dysautonomia in Parkinson's disease: neurocardiological abnormalities.  Lancet Neurol. 2003;  2 669-676
    CrossrefPubMedGoogle Scholar
  • 76 Jancovic J, Gilden J L, Hiner B C. et al . Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine.  Am J Med. 1993;  95 38-48
    CrossrefPubMedGoogle Scholar
  • 77 Low P A, Gilden J L, Freeman R. et al . Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.  JAMA. 1997;  277 1046-1051
    CrossrefPubMedGoogle Scholar
  • 78 Hussain I F, Brady C M, Swinn M J. et al . Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension.  J Neurol Neurosurg Psychiatry. 2001;  71 371-374
    CrossrefPubMedGoogle Scholar
  • 79 Tandberg E, Larsen J P, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease.  Mov Disord. 1998;  13 895-899
    CrossrefPubMedGoogle Scholar
  • 80 Schapira A H. Excessive daytime sleepiness in Parkinson's disease.  Neurology. 2004;  63 (8, Suppl 3) S24-27
    PubMedGoogle Scholar
  • 81 Schenck C H, Bundlie S R, Ettinger M G. et al . Chronic behavioral disorders of human REM sleep: a new category of parasomnia.  Sleep. 1986;  9 293-308
    PubMedGoogle Scholar
  • 82 Factor S A, McAlarney T, Sanchez-Ramos J R. et al . Sleep disorders and sleep effect in Parkinson's disease.  Mov Disord. 1990;  5 280-285
    CrossrefPubMedGoogle Scholar
  • 83 Hogl B, Seppi K, Brandauer E. et al . Increased daytime sleepiness in Parkinson's disease: a questionnaire survey.  Mov Disord. 2003;  18 319-323
    CrossrefPubMedGoogle Scholar
  • 84 Frucht S, Rogers J D, Greene P E. et al . Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole.  Neurology. 1999;  52 1908-1910
    PubMedGoogle Scholar
  • 85 Hobson D E, Lang A E, Martin W R. et al . Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group.  JAMA. 2002;  287 455-463
    CrossrefPubMedGoogle Scholar
  • 86 Adler C H, Caviness J N, Hentz J G. et al . Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.  Mov Disord. 2003;  18 287-293
    CrossrefPubMedGoogle Scholar
  • 87 Paus S, Brecht H M, Koster J. et al . Sleep attacks, daytime sleepiness, and dopamine agnostis in Parkinson's disease.  Mov Disord. 2003;  18 659-667
    CrossrefPubMedGoogle Scholar

Dr. med. Gisa Ellrichmann

Neurologische Klinik St. Josef-Hospital

Gudrunstraße 56

44791 Bochum

Email: gisa.ellrichmann@rub.de